September 2008 malaria vaccine news

Stories and articles on malaria vaccine developments around the world

Innovative finance for women and children
September 27, 2008–October 3, 2008 – As a result of unprecedented global commitments and funding for infectious diseases and vaccinations, some countries are making good progress—particularly in reducing deaths from HIV/AIDS, malaria, tuberculosis, and vaccine-preventable diseases. Additionally, a range of innovative financing mechanisms are being developed to attract, channel, and use additional resources in new ways.
The Lancet

World on ‘the brink’ of eliminating malaria deaths, says UN envoy
Friday, September 19, 2008 – Leading figures from government, business and civil society will meet next week in New York to highlight how close the world is to ending malaria deaths by the target date of 2015, a goal that the United Nations special envoy for the disease says is clearly within reach.
UN News Center

Global malaria estimates are reduced
Thursday, September 18, 2008 –The World Health Organization (WHO) has cut its global estimate of yearly malaria cases by more than 100 million, according to a report released Thursday by the health agency.
Time

Nicolas Sarkozy launches international malaria campaign
Thursday, September 11, 2008 – French president Nicolas Sarkozy launched a campaign, titled "To Decide Is to Win: Together, Let's Make Malaria a Disease of the Past." The campaign aims to ensure the availability of malaria drugs for low-income people with the disease.
News-Medical.net

War against malaria
Tuesday, September 9, 2008 – French researchers at the Pasteur Institute have reported trials of a malarial vaccine that mimics the natural immunity some people develop against the disease. However, the vaccine would need to undergo a series of further rigorous trials before it is accepted for routine administration.
Central Chronicle

Var2CSA DBL6-epsilon domain expressed in HEK293 induces limited cross-reactive and blocking antibodies to CSA binding parasites
Thursday, September 4, 2008 – Recent works point to the variant protein var2CSA as the key target for the development of a pregnancy-associated malaria vaccine. However, designing such a prophylactic vaccine has been hindered by the difficulty in identifying regions of var2CSA that could elicit broadly neutralizing and adhesion-blocking antibodies.
Malaria Journal 2008; 7:170